Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 5/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.50 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrogen Peroxide SCHEMBL14842577 | 1.00 | OPRL1 (0.55) | OPRL1OPRM1OPRK1OPRD1AKR1C1 | |
| SCHEMBL1040024 | 1.00 | OPRL1 (0.55) | OPRL1OPRM1OPRK1OPRD1AKR1C1 | |
| SCHEMBL29195226 | 1.00 | OPRL1 (0.55) | OPRL1OPRM1OPRK1OPRD1AKR1C1 | |
| SCHEMBL16469256 | 1.00 | OPRL1 (0.55) | OPRL1OPRM1OPRK1OPRD1AKR1C1 | |
| SCHEMBL4556223 | 1.00 | OPRL1 (0.55) | OPRL1OPRM1OPRK1OPRD1AKR1C1 | |
| SCHEMBL60129 | 1.00 | OPRL1 (0.55) | OPRL1OPRM1OPRK1OPRD1AKR1C1 | |
| SCHEMBL1109741 | 0.97 | OPRL1 (0.57) | OPRL1OPRM1OPRK1OPRD1AKR1C1 | |
| SCHEMBL1724862 | 0.92 | OPRL1 (0.57) | OPRL1OPRM1OPRK1OPRD1AKR1C1 | |
| Ethylene Glycol SCHEMBL28317982 | 0.91 | OPRL1 (0.49) | OPRL1OPRM1OPRK1OPRD1AKR1C1 | |
| Ammonia Solution, Strong SCHEMBL29195223 | 0.90 | OPRL1 (0.55) | OPRL1OPRM1OPRK1OPRD1AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130030001-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130030001-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130030001-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130005695-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2013-01-03 | — | — | US | disclosed |
| US-20130005695-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2013-01-03 | — | — | US | disclosed |
| US-20130005695-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2013-01-03 | — | — | US | disclosed |
| US-8329729-B2 | Quinuclidine derivatives as muscarinic M3 receptor antagonists | ASTRAZENECA AB (SE) | 2012-12-11 | — | — | US | disclosed |
| US-8329729-B2 | Quinuclidine derivatives as muscarinic M3 receptor antagonists | ASTRAZENECA AB (SE) | 2012-12-11 | — | — | US | disclosed |
| US-8329729-B2 | Quinuclidine derivatives as muscarinic M3 receptor antagonists | ASTRAZENECA AB (SE) | 2012-12-11 | — | — | US | disclosed |
| US-8207193-B2 | Quiniclidine derivatives of (hetero) arylcycloheptanecarboxylic acid as muscarinic receptor antagonists | ASTRAZENECA AB (SE) | 2012-06-26 | — | — | US | disclosed |
| WO-2009139709-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009139709-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009138707-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009138707-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
| EP-2094694-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008059239-A1 | NOVEL COMPOUNDS 514 | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008059239-A1 | NOVEL COMPOUNDS 514 | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008059245-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008059245-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | WO | disclosed |
| CN-100999452-A | Method of synthesizing seratrodast | UNIV CHONGQING (CN) | 2007-07-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130030001-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM5 | OPRL1 60/4885OPRM1 43/4885OPRK1 61/4885 |
| US-20130005695-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | OPRL1 93/4885OPRM1 52/4885OPRK1 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.